NIH SBIR/STTR Omnibus Solicitation

NIH SBIR/STTR Omnibus Solicitation

Overview in plain English

The NIH SBIR/STTR omnibus opportunity is the broadest entry point into NIH funding for U.S. small businesses that are building health-related technologies in an early to mid proof-of-concept stage. You can think of it as NIH’s “regular lane” for unsolicited, investigator-initiated proposals when your idea is strong enough to compete but not yet tied to one narrow program announcement.

This is not a single grant number you submit once and wait forever. It is a recurring federal funding framework that points to active NOFOs (notices of funding opportunities) when they are open. When the page says “no opportunities found,” it means no grant announcements are currently published for submission right now, not that the program is unusable.

As of the most recent official NIH source check, NIH says SBIR and STTR were reauthorized on April 13, 2026, and that there were no active SBIR/STTR NOFOs at that moment; the next standard receipt date listed was September 5, 2026.

At-a-glance summary

What this gives you and what it does not

You are applying for a structured, federal program that is designed to fund the early commercial development of biomedical technologies. It is not a guarantee of funding, a guaranteed purchase agreement, or a program for open-ended grants. NIH funding does not buy your company; it buys a specific set of R&D activities and expects measurable progress.

Use this if your project has this shape:

• A technical idea with clear potential users or a problem statement.
• A path from prototype, assay, or platform to clinical/translational evidence.
• A timeline that can deliver objective milestones and outcomes.

Avoid this if your project is purely exploratory with no credible path to execution, or if you are not ready to meet federal-level compliance and reporting expectations.

Why this matters for founders and teams

The opportunity is one of the few pathways where a biomedical small business can get federal support without surrendering equity. Teams use it when:

• Venture funding is not yet available enough to complete early science.
• Internal budget is insufficient for full proof-of-concept work.
• The science has clear translational or commercialization potential.

Because this process is rules-heavy, disciplined teams often get the largest advantage over equally technical competitors. Success usually depends less on “idea quality” alone and more on execution quality: clear scope, realistic milestones, and a proposal format that matches NIH expectations.

Who this opportunity is for

This route is most suitable when you can answer all of these with confidence:

• Do we have a credible technical problem and a concrete userspace in healthcare, diagnostics, devices, therapeutics, digital health, or related biomedical R&D?
• Can we define milestones for a near-term review period that a panel can verify?
• Are we willing and able to provide compliant registration and submission artifacts?

It is generally good fit for:

• For-profit U.S. small businesses.
• Teams led by founders willing to run NIH-style applications and updates.
• Ideas that benefit from NIH review standards and network alignment with NIH Institutes and Centers.

It is generally poor fit for:

• Teams seeking pure grant-style funding with no commercialization path.
• Companies that cannot commit to the application timeline or documentation standards.
• Firms that cannot distinguish what is required by a parent NOFO versus a topic-specific NOFO.

Eligibility and program basics (the parts people often misread)

1) Small business requirements are strict and mechanical

The NIH SEED page is clear that only U.S. small business concerns can submit. NIH points to SBA rules for ownership, size, and other definitions. In practical terms, teams should validate:

• Organized for profit and U.S.-based for award purposes.
• Eligible ownership and affiliation structure under SBA Part 121 guidance.
• Employee and affiliate limits.
• Any venture-capital, hedge fund, or private-equity ownership restrictions that apply to your legal structure.

The seed page also highlights performance benchmark rules used by SBA/HHS across SBIR/STTR. If your company has many prior Phase I/II awards, transition and commercialization benchmark rules can reduce eligibility for a filing cycle.

2) SBIR and STTR differ in partner rules

A critical difference is how research partnerships with nonprofit institutions are treated:

• SBIR: partnerships with research institutions are allowed.
• STTR: meaningful collaboration with a research institution is required.
• In NIH terms, this affects ownership, PI role, and expected work split.

NIH materials describe different PI employment and work-share conditions across SBIR versus STTR, and the correct interpretation is always in the NOFO instructions. Do not rely on memory or old templates; read the active NOFO and the specific section that governs PI responsibility.

3) Clinical trial status and special handling vary by solicitation

Some solicitation documents require specific clinical-trial handling and some restrict it. That is NOFO-level logic, not a universal rule across the entire program. Always check:

• Funding opportunity text, especially Section IV (Application and Submission Information).
• Related notices in the NIH Guide.
• The relevant Notices section in your assigned Institute/Center interest page.

If you force an assumption here (for example, that a project is automatically allowed for clinical work), you risk a avoidable rejection point.

How to decide whether to apply (a practical filter)

Before you even start writing, score your readiness from 0–3 in each row:

1. Problem clarity
2. Technical risk management
3. Regulatory and compliance capacity
4. Submission timeline control
5. Commercial realism
6. Registration readiness

If you cannot score at least three items at 2+ out of 3, pause and prepare first. NIH does not reject only weak science; it often rejects weak readiness.

A strong readiness profile looks like this:

• Your problem is narrow enough to be measurable.
• Your team can explain exactly what “success” looks like by proposal period.
• Your registration stack (SAM, eRA Commons, Grants.gov, SBA registrations) is already in progress or complete.
• You know which nofo type you are applying to before proposal writing starts.

The route decision: parent announcement vs specific NOFO

NIH’s own framework separates these clearly:

Parent announcements (omnibus)

These are investigator-initiated and broader in topic framing. You use them when your idea is not tied to a tightly defined topic and you can still map your approach to NIH priorities.

Specific opportunities (RFA/PAS/PAS-linked)

These are narrow, often topic-specific, and can include stricter scope constraints, review expectations, and budgets.

How to choose

• Use the parent lane if your innovation is broadly applicable and you need the flexibility.
• Use specific NOFO lane if you have a strong match to a clear announced theme and want targeted competition.

Choosing wrong is one of the most expensive errors because you burn time on the wrong instructions.

Confirm active status before you write a line of proposal prose

When this is active:

1. Confirm the NOFO number and title from SEED and/or Grants.gov.
2. Pull the NIH NOFO package and read the key sections.
3. Confirm whether the mechanism is SBIR or STTR and what phase is open (Phase I, Fast Track, direct Phase II, etc.).

When no NOFO is active:

• Do not submit just to keep moving.
• Build a “ready-to-submit” package for the next cycle.

The most useful thing you can do in this phase is preparation, because the window opens quickly and closes quickly.

Step-by-step application process (practical)

Step 1: Registration and system readiness (must be done early)

NIH explicitly lists registrations as a prerequisite for application prep and submission. Your stack usually includes:

• SAM.gov registration.
• eRA Commons.
• Grants.gov credentials/eligibility through required channels.
• SBA control identification for small business programs.

Teams lose valuable time when registrations are incomplete close to deadline. Set internal deadlines at least 2–3 weeks before the final date for completion.

Step 2: Select the right instruction set

NIH says to use the NIH Application Guide and the SBIR/STTR instruction set, with NOFO instructions taking precedence when there is conflict.

It also notes that form versions changed around the January 24/25, 2025 deadline boundary. Because this can change by cycle, treat the active NOFO as the deciding source.

Step 3: Build with the right submission path

NIH indicates two options for electronic submission:

• ASSIST for a large share of HHS small-business applicants.
• Grants.gov Workspace / system-to-system methods.

NIH makes it explicit: mail-in submission is not an option.

Step 4: Draft around reviewability, not verbosity

Your proposal should be reviewable by a busy reviewer:

• Clear problem statement with specific clinical or user pain.
• Defined aims and milestones per phase.
• Evidence plan that states what exists, what is missing, and how missing evidence will be generated.
• Commercial rationale for the next step after NIH funding.
• Work-plan split that respects SBIR/STTR rules.

Step 5: Internal technical + compliance review

Do not skip this. Build a two-pass review:

• Technical pass: does the plan solve the stated problem?
• Compliance pass: does the packet match required forms, checklists, and NOFO-specific instructions?

Step 6: Submit and verify

Submit through the official system, capture the receipt, and track your status via NIH/ERA channels.

Step 7: After submission

Use the submitted materials as a living package:

• Respond quickly to administrative or scientific follow-up requests.
• Keep clean versioning of attachments and evidence.
• Maintain a single person accountable for status tracking and communications.

Required materials and planning checklist

Below is a practical baseline checklist based on official NIH guidance and common submission mechanics.

• Opportunity package: NOFO, NIH Application Guide references, Section IV and FAQ sections.
• Title page and abstract that map directly to the scope.
• Project narrative that separates scientific objectives and commercialization logic.
• Budget and budget justification tied to tasks.
• Team and roles, including PI and subcontracting relationships.
• Regulatory readiness: if human subjects or clinical work is involved, include complete relevant documents.
• Data-management and commercialization follow-through notes.
• STTR agreements and collaboration documents where required.

For NIH small-business applicants, this check is usually where applications are won or lost. If your proposal “sounds impressive” but is missing a required section, it fails to score well even with strong science.

Readiness to apply: common mistakes to avoid

1. Submitting without registrations complete.
2. Ignoring the active/inactive NOFO state and writing against the wrong mechanism.
3. Treating STTR and SBIR partner expectations as identical.
4. Assuming all NIH NOFOs accept the same clinical trial posture.
5. Missing the shifted deadline rule (weekend/holiday moved to next business day).
6. Overloading the proposal with broad science and under-defining milestones.
7. Confusing eligibility with “how much I wish” instead of checking SBA and program rules directly.

The recurring pattern is that applicants lose points on structure and compliance, not only on raw science.

At-a-glance readiness matrix

Use this as a pre-submission filter in the final 72 hours:

• I confirmed a live NOFO and its exact mechanism.
• My team has verified SBIR/STTR mechanism eligibility under SBA and NIH rules.
• STTR collaborators are in place where required and documented.
• Registrations are complete (SAM, eRA Commons, SBA control ID, Grants.gov access).
• PI role, workshare, and budget align with the active NOFO.
• I reviewed NIH Application Guide and the applicable SBIR/STTR instruction set.
• I completed at least one compliance-focused pre-review.
• I tested submission path and validated confirmation behavior.
• I have a response owner for review questions and an escalation path for system issues.

Timeline model

If a NOFO opens, use a realistic schedule:

• Weeks 1–2: Confirm the exact opportunity and map scope.
• Weeks 3–4: Register/verify systems, define milestones, write first pass.
• Weeks 5–6: Budget, compliance, and draft attachments.
• Weeks 7–8: Internal reviews and revisions.
• Weeks 9–10: Final form validation and pre-submission checks.
• Week 11: Submit early (ideally at least one business day before official date).

For specific NOFOs with strict topic requirements, compress this timeline and build earlier contingency time for external science review.

FAQ

Why is the page showing “no opportunities found” but there is still no deadline?

That means there is no currently open solicitation for submission under this page at that moment. NIH usually publishes future opportunities first on Grants.gov. It does not mean the program is inactive in the long term.

What should I do while waiting?

Use waiting time to complete registrations, clean proposal artifacts, and align your team with the PI/partner structure and compliance checklist. This reduces panic when the announcement opens.

Is this route only for NIH-funded technologies?

No. The route is generally for early-stage technologies with strong scientific and commercialization logic. Prior funding may help, but it is not the only path.

Can STTR and SBIR both use the same submission system?

Yes, both route through NIH systems, but the instructions differ by mechanism. The active NOFO text is what determines PI roles and partner expectations.

If there is no active NOFO, can I still contact NIH?

Yes, use the official support pathways on NIH/SEED pages to ask pre-application or mechanism questions and to confirm fit.

How often do deadlines move?

NIH states deadlines are on Sept 5, Jan 5, and Apr 5, and dates that fall on weekends or federal holidays move to the next business day.

What to do next

If you are ready now

• Subscribe to official updates from SEED and monitor Grants.gov forecast releases.
• Define your project in one sentence: problem, user, milestone, and proof point.
• Keep your registrations current and test one system check-in before the cycle opens.

If your project is not a fit yet

• Tighten the PI role and ownership model first.
• Clarify partner expectations for STTR.
• Add missing bench-to-human evidence milestones.
• Reassess after the next NOFO announcement.

Official links you should bookmark now

• NIH SBIR/STTR funding opportunities (NIH SEED)
• How to apply (NIH SEED)
• Prepare your application (NIH SEED)
• NIH Application Guide
• NIH SBIR/STTR instruction pages are linked from NOFO text and the NIH Application Guide; use those links plus Section IV of your active NOFO for the official filing requirements
• NIH Guide for Grants & Contracts
• NIH parent announcements and specific small-business opportunities
• NIH HHS Small Business Program contact list and considerations
• Eligibility criteria and ownership considerations (NIH SEED)

Final decision guide

At a glance, this opportunity is worth your time when three conditions are true:

1. You have a defined biomedical problem and a measurable development path.
2. Your ownership and partnership structure can pass SBA/NIH rules for the mechanism you need.
3. You are ready to execute a strict federal submission process without last-minute scrambling.

If one condition is still weak, use this cycle to fix it first. NIH application windows are short and often repeat, so preparing well is a real advantage when the page changes from “no active opportunities” to open and accepting.